[go: up one dir, main page]

ES2120948T3 - Procedimiento y composiciones que mejoran los sintomas de la sepsis. - Google Patents

Procedimiento y composiciones que mejoran los sintomas de la sepsis.

Info

Publication number
ES2120948T3
ES2120948T3 ES90911485T ES90911485T ES2120948T3 ES 2120948 T3 ES2120948 T3 ES 2120948T3 ES 90911485 T ES90911485 T ES 90911485T ES 90911485 T ES90911485 T ES 90911485T ES 2120948 T3 ES2120948 T3 ES 2120948T3
Authority
ES
Spain
Prior art keywords
sepsis
symptoms
compositions
procedure
improve
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES90911485T
Other languages
English (en)
Inventor
Richard Ulevitch
Peter Tobias
Samuel D Wright
John C Mathison
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rockefeller University
Scripps Research Institute
Original Assignee
Rockefeller University
Scripps Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rockefeller University, Scripps Research Institute filed Critical Rockefeller University
Application granted granted Critical
Publication of ES2120948T3 publication Critical patent/ES2120948T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Two-Way Televisions, Distribution Of Moving Picture Or The Like (AREA)

Abstract

ESTA INVENCION DESCRIBE UN METODO PARA TRATAR LA SEPSIS QUE COMPRENDE EL ADMINISTRAR UNA CANTIDAD TERAPEUTICAMENTE EFICAZ DE MOLECULAS DE ANTICUERPO ANTI-CD14. SE DESCRIBE TAMBIEN UNA COMPOSICION TERAPEUTICA COMPRENDIENDO MOLECULAS DE ANTICUERPO ANTI-CD14 EN UN EXCIPIENTE FARMACEUTICAMENTE ACEPTABLE.
ES90911485T 1989-08-01 1990-07-30 Procedimiento y composiciones que mejoran los sintomas de la sepsis. Expired - Lifetime ES2120948T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US38781789A 1989-08-01 1989-08-01

Publications (1)

Publication Number Publication Date
ES2120948T3 true ES2120948T3 (es) 1998-11-16

Family

ID=23531466

Family Applications (1)

Application Number Title Priority Date Filing Date
ES90911485T Expired - Lifetime ES2120948T3 (es) 1989-08-01 1990-07-30 Procedimiento y composiciones que mejoran los sintomas de la sepsis.

Country Status (14)

Country Link
US (4) US5730980A (es)
EP (1) EP0485430B1 (es)
JP (1) JP2744130B2 (es)
AT (1) ATE171042T1 (es)
AU (1) AU645515B2 (es)
CA (1) CA2022429C (es)
DE (1) DE69032662T2 (es)
DK (1) DK0485430T3 (es)
ES (1) ES2120948T3 (es)
FI (1) FI920450A0 (es)
GR (1) GR1003164B (es)
IE (1) IE902770A1 (es)
PT (1) PT94869B (es)
WO (1) WO1991001639A1 (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2120948T3 (es) * 1989-08-01 1998-11-16 Scripps Research Inst Procedimiento y composiciones que mejoran los sintomas de la sepsis.
DE4029227A1 (de) * 1990-09-14 1992-03-19 Imtox Gmbh Arzneimittel enthaltend cd14
CA2133758A1 (en) * 1992-04-06 1993-10-14 Sanna M. Goyert A novel therapy for treating sepsis using a soluble form of recombinant cd14 myelomonocytic antigen
CA2163976C (en) * 1993-05-28 2010-06-29 Didier J. Leturcq Methods and compositions for inhibiting cd14 mediated cell activation
US5731415A (en) * 1993-06-17 1998-03-24 Xoma Corporation Lipopolysaccharide binding protein derivatives
US5891618A (en) 1994-01-24 1999-04-06 Xoma Corporation Method for quantifying LBP in body fluids
US5484705A (en) * 1994-01-24 1996-01-16 Xoma Corporation Method for quantifying lipopolysaccharide binding protein
EP0792162B1 (en) 1994-09-16 2005-11-09 The Scripps Research Institute Use of antibodies to block the effects of gram-positive bacteria and mycobacteria
US5766593A (en) * 1994-12-30 1998-06-16 Amgen Inc. Anti-inflammatory CD14 peptides
CA2208699A1 (en) * 1994-12-30 1996-07-11 Rockefeller University (The) Anti-inflammatory cd14 polypeptides
AU5688596A (en) * 1995-04-13 1996-10-30 Deutsche Om Arzneimittel Gmbh Anti-cd14 antibodies for use in the induction of il-10 secre tion
AU6392996A (en) * 1995-06-19 1997-01-15 Sanna M. Goyert A method for inhibiting bacteremia and bacterial dissemination
ES2153665T3 (es) * 1996-05-10 2001-03-01 Xoma Technology Ltd Usos terapeuticos de productos proteicos bactericidas/incrementadores de la permeabilidad (bpi) para la meningococemia humana.
AU736096B2 (en) * 1996-05-23 2001-07-26 Xoma Corporation Therapeutic uses of BPI protein products in humans with hemorrhage due to trauma
US6093693A (en) * 1996-11-18 2000-07-25 The Wellesley Hospital Foundation B cell activation
US6991790B1 (en) * 1997-06-13 2006-01-31 Genentech, Inc. Antibody formulation
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
US5990082A (en) 1997-10-22 1999-11-23 Xoma Corporation Uses of lipopolysaccharide binding protein
EP1052984B1 (en) * 1998-02-07 2004-05-12 Vernalis (Oxford) Ltd Antibacterial agents
AU771448B2 (en) * 1998-05-27 2004-03-25 Gemma Biotechnology Ltd. The induction of antibiotic proteins and peptides by LAIT/sCD14-protein
US6974698B1 (en) * 1999-01-15 2005-12-13 The United States Of America As Represented By The Department Of Health And Human Services Methods for delivering biologically active molecules into cells
EP1213586A4 (en) 1999-09-17 2003-02-05 Mochida Pharm Co Ltd METHOD FOR FRACTIONAL MEASUREMENT OF SOLUBLE CD14 PROTEIN
AU2001290315A1 (en) * 2000-11-22 2002-06-03 Mochida Pharmaceutical Co., Ltd. Anti-cd14 monoclonal antibody having effect of inhibiting cd14/tlr binding
AU2002221099A1 (en) * 2000-12-08 2002-06-18 Takeda Chemical Industries Ltd. Combination drugs
EP1542721A4 (en) * 2002-06-14 2007-05-02 Centocor Inc MODIFIED "S" ANTIBODIES
ES2522525T3 (es) 2003-05-15 2014-11-14 Genentech, Inc. Métodos y composiciones para la prevención y el tratamiento de la sepsis
US20060206947A1 (en) * 2005-02-28 2006-09-14 Scallon Bernard J Heterodimeric protein binding compositions
US7696211B2 (en) * 2005-04-29 2010-04-13 Wilson Constance N Methods and pharmaceutical compositions for treating sepsis
WO2006129849A1 (ja) 2005-06-03 2006-12-07 Mochida Pharmaceutical Co., Ltd. 抗ｃｄ１４抗体融合蛋白質
WO2015140591A1 (en) * 2014-03-21 2015-09-24 Nordlandssykehuset Hf Anti-cd14 antibodies and uses thereof
EP3612566A4 (en) * 2017-04-21 2021-03-03 Implicit Bioscience Limited CD14 ANTAGONIST ANTIBODIES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5057598A (en) * 1983-05-06 1991-10-15 Centocor, Inc. Monoclonal antibodies reactive with endotoxin core
US4918163A (en) * 1985-09-27 1990-04-17 Pfizer Inc. Monoclonal antibodies specific for lipid-A determinants of gram negative bacteria
US4834976A (en) * 1986-07-03 1989-05-30 Genetic Systems Corporation Monoclonal antibodies to pseudomonas aeruginosa flagella
ES2120948T3 (es) * 1989-08-01 1998-11-16 Scripps Research Inst Procedimiento y composiciones que mejoran los sintomas de la sepsis.

Also Published As

Publication number Publication date
DE69032662D1 (de) 1998-10-22
JP2744130B2 (ja) 1998-04-28
PT94869A (pt) 1991-04-18
EP0485430B1 (en) 1998-09-16
AU6146190A (en) 1991-03-11
DK0485430T3 (da) 1999-06-14
GR900100582A (el) 1991-12-30
US6297049B1 (en) 2001-10-02
PT94869B (pt) 1997-04-30
IE902770A1 (en) 1991-02-27
DE69032662T2 (de) 1999-03-11
US6045795A (en) 2000-04-04
CA2022429C (en) 1998-12-01
FI920450A0 (fi) 1992-01-31
CA2022429A1 (en) 1991-02-02
GR1003164B (el) 1999-07-05
EP0485430A4 (en) 1993-03-03
AU645515B2 (en) 1994-01-20
ATE171042T1 (de) 1998-10-15
US20020034509A1 (en) 2002-03-21
WO1991001639A1 (en) 1991-02-21
EP0485430A1 (en) 1992-05-20
JPH05501399A (ja) 1993-03-18
US6495332B2 (en) 2002-12-17
US5730980A (en) 1998-03-24

Similar Documents

Publication Publication Date Title
ES2120948T3 (es) Procedimiento y composiciones que mejoran los sintomas de la sepsis.
DE69231062D1 (de) Morphogen-induzierte Modulation von entzündlichen Antworten
EP0938505A4 (en) MONOCLONAL ANTIBODIES AGAINST ENDOGLIN AND THEIR USE IN ANTIANGIOGENIC THERAPY
IT1281188B1 (it) Composizione per prevenire e trattare infiammazioni con immunoglobulina a.
ATE111735T1 (de) Verwendung des wirkstoffs azelastin und glycerinethern zur bekämpfung von psoriasis- erkrankungen.
DK0502925T3 (da) præparat til behandling af inflammatoriske tarmlidelser
DK1167354T3 (da) Racemisk huperzin A
IE802589L (en) Anti-inflammatory pharmaceutical composition containing¹rosmarinic acid
ES2139674T3 (es) Metodo para tratar la sintomatologia del sindrome premenstrual con vitamina d o vitamina d y calcio.
FI920139A0 (fi) Foerfaranden foer behandling och foerfindrande av autoimmun uveoretinitis hos daeggdjur.
ES555118A0 (es) Metodo de preparar medicamentos que incluyen un agente buscador de hueso y un inhibidor de anhidrasa carbonica, para impedir y curar enfermedades oseas.
UA26403A (uk) Похідhі n-заміщеhого 4-феhіл-4-піперидиhкарбоксаміду та їх фармацевтичhо прийhятhі солі, що проявляють аhестезувальhу та аhальгезувальhу дію, спосіб їх одержаhhя та фармацевтичhа композиція
DK319484D0 (da) Imidazol-2-ylthioalkansyrer, fremgangsmaade til deres fremstilling samt farmaceutiske praeparater indeholdende disse
DE69534601D1 (de) Gebrauch von antikörpern zur verhinderung von auswirkungen hervorgerufen durch grampositive- und myko-bakterien
MD960168A (ro) Metodă şi compuşi pentru tratamentul infecţiilor virale
DK0643585T3 (da) Anvendelsen af lipoprotein-associeret koagulationsinhibitor (LACI) til fremstilling af et lægemiddel til behandlingen af ak
NO921223D0 (no) Kombinasjonspreparat med antitrombotisk virkning
MX9302985A (es) Composicion farmaceutica para el tratamiento y la profilaxis de la ansiedad.
ES535091A0 (es) Procedimiento de obtencion de una fraccion de hidrocarburos a partir de cera de abeja.
DE59005233D1 (de) Neue Acylaminosäurederivate enthaltende Arzneimittel und Diätetika.
FR2303558A1 (fr) Preparation therapeutique pour traiter l'infection sous forme de pneumonie hemorragique du vison et de mastite bovine causees par la pseudomonas aeruginosa
FR2422628A1 (fr) Esters benzylideniques et leur application en therapeutique
IT1216233B (it) Utilizzazione della forma farmaceutica 'gel'contenente acido n (2,6 dicloro m tolil) antranilico (acido meclofenamico) impiegabile in terapia per uso topico.
GR1000305B (el) Μεθοδος παρασκευης συνθεσεως για την ελαττωση της φλεβεκτασιας.
ECSP972109A (es) Estimulacion de los mecanismos de defensa del huesped contra tumores

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 485430

Country of ref document: ES